Oncotarget

Research Papers:

Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer

Hong Zheng, Xin Liu, Jianhong Zhang, Shawn J. Rice, Matthias Wagman, Yaxian Kong, Liuluan Zhu, Junjia Zhu, Monika Joshi and Chandra P. Belani _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:56233-56240. https://doi.org/10.18632/oncotarget.9316

Metrics: PDF 1706 views  |   HTML 1283 views  |   ?  


Abstract

Hong Zheng1,*, Xin Liu1,*, Jianhong Zhang1, Shawn J. Rice1, Matthias Wagman1, Yaxian Kong2, Liuluan Zhu2, Junjia Zhu1, Monika Joshi1, Chandra P. Belani1

1Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA, USA

2Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China

*These authors have contributed equally to this work

Correspondence to:

Chandra Belani, e-mail: cbelani@psu.edu

Keywords: PD-1, peripheral blood, T cells, prognosis, NSCLC

Received: February 12, 2016     Accepted: April 13, 2016     Published: May 12, 2016

ABSTRACT

Recent success of using agents inhibiting the major immune check point, programmed cell death-1 (PD-1) pathway, offers a great promise for effective cancer therapy. Two blocking antibodies for PD-1, nivolumab and pembrolizumab have recently been approved for treating advanced recurrent non-small cell lung cancer (NSCLC). Activation of PD-1 on T cells and PD-L1 on tumor cells or antigen presenting cells leads to T cell exhaustion and ultimately tumor growth. In this study, we performed flow cytometry analysis of peripheral blood samples collected from patients with advanced NSCLC at initial diagnosis. We report that surface expression of PD-1 on CD4+ T cells has a prognostic value in NSCLC patients, as high expression of PD-1 is associated with a shorter progression-free survival and overall survival. Importantly, we also found that high PD-1 expression on peripheral CD4+ T cells is associated with inferior clinical response in a subset of patients who received anti-PD-L1 treatment, indicating a potential predictive value of this marker. This work highlights the potential of a non-invasive and effective method to determine prognostic and predictive biomarkers for inhibiting the PD-1 pathway in NSCLC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9316